Genome sequencing has moved from bench research into clinical care—and it’s producing medical miracles. Now, it’s time to make genome sequencing an everyday part of our clinical workflows. That day is closer than you might think.
Those were the messages James Lowey shared at HIMSS 2015 in Chicago. As VP of technology at TGen—the nonprofit Translational Genomics Research Institute—James is at the forefront of efforts to bring next-generation genomic sequencing into the clinical mainstream and use it to transform the way we diagnose, treat, and prevent illness.
At the HIMSS session, James described the broad range of areas of clinical interest for genomic data. He also discussed the compute infrastructure necessary to provide cost-effective performance and scalability for large-scale production processing of genomic data.
Recently, our healthcare team interviewed James to learn more about his TGen’s strategy. In this case study, James tells us where he thinks we’re heading—and how fast we’re getting there. He also highlights social and policy issues that must be addressed, and points out the need for ongoing research to establish evidence-based clinical protocols.
I hope you’ll read the TGen case study and join the conversation. Is your organization incorporating genomic analysis into clinical workflows? If so, can you share any advice or best practices? If not, how close are you? What are your next steps? What’s holding you back? Let me know in the comments section. Or become a member of the Intel Health and Life Sciences Community.
Learn more about Intel® Health & Life Sciences.
Download the session handout from HIMSS 2015, Using Genomic Data to Make a Difference in Clinical Care.
Stay in touch: @IntelHealth, @hankinjoan